Some individuals may attempt to use doses lower than the licensed starting doses or remain at the initial dose indefinitely, rather than following the licensed escalation protocol
After treating patients with infertility and obesity for more than 15 years, one thing is clear, Kumar said: These patients are becoming very fertile. Pregnant people and those planning to get pregnant were excluded from trials of GLP-1s
If these results hold up in larger trials, triple agonists may become the most effective non-surgical weight loss treatment available
Traditional methods may be important, but they cant control how hormones, metabolism, and appetite signals influence body weight
A First Look at the Numbers A 2026 study published in The Lancet Obstetrics, Gynaecology, and Women's Health took a direct look at this question, evaluating 120 postmenopausal women treated with tirzepatide, one of the most effective GLP-1 and GIP dual receptor agonists currently available [16]
